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Abstract  
Several lines of evidence suggest that it is time to re-examine the approach to the patient diagnosed with distant metastases at 
the initial breast cancer presentation. 
The aim of this study was to evaluate the impact of surgical therapy of the primary tumor and other clinical and staging 
factors on overall survival of patients with stage IV breast cancer. Patients and methods: This retrospective study included 
patients with stage IV breast cancer from 2000 to 2008. Patient's characteristics and survival distilled from medical files were 
evaluated using multivariate analysis.  
Results: Of 330 patients included in this study, 132 underwent surgery in the form of mastectomy. Local surgery of the 
primary tumor, lower TN staging, younger age, positive receptor status, lack of Her-2 amplification, bone –only metastasis 
and one site metastasis were associated with significantly higher survival while grade and pathological type were not. Median 
overall survival time for no surgery group was 15 months and 27 months for mastectomy group (P = 0.003).Three-year 
survival rate was higher for patients who did have surgery (34% vs 16%). Conclusion: Removal of the primary tumor in 
patients with primary distant metastatic breast cancer was associated with significantly higher survival. However, carefully 
designed prospective randomized trials are needed to confirm these results. 
 
 
   American Journal of 
Cancer Therapy and Ph rm col g
 
Research Article 
 
American Journals of  
Cancer Therapy and Pharmacology 
http://ivyunion.org/index.php/ ajctp  
Vol. 2, Article ID 201300249, 7 pages 
 Elawadi M et al. American Journal of Cancer Therapy and Pharmacology 2014, 2:1-7 
  
Ivy Union Publishing | http: //www.ivyunion.org February 22, 2014 | Volume 2 | Issue 1  
Page 2 of 7 
Introduction 
With an increasing incidence, breast cancer is still 
the number one cancer affecting women in the 
western world. Of all these women, 3-10% had 
distant metastases at initial presentation [1]. The 
vast majority of patients with metastatic breast 
cancer do not survive beyond 5 years after 
diagnosis [2]. 
Traditionally, metastatic breast cancer (MBC) is 
considered to be incurable and the goals of 
treatment are the prolongation of life and the 
palliation or prevention of symptoms. In stage IV 
disease, local surgery is reserved for patients who 
develop complications such as bleeding, ulceration 
and infection at the primary tumor site, a type of 
surgery that historically has been described as 
"toilette" mastectomy. If the total tumor burden 
plays a role in survival, the removal of the breast 
lesion is a part of a multimodality strategy in 
preventing further growth and dissemination of the 
disease [3]. A strong correlation was found between 
the level of circulating tumor cells (CTCs) and the 
prognosis of MBC; the number of CTCs before 
treatment is an independent of overall survival in 
these patients [4-6]. 
Improved survival can also be caused by the fact 
that surgical resection restores the immune system 
[7]. Tumor-induced immunosuppression is a 
mechanism allowing tumors to escape immune 
destruction. It is reasonable that 
immunosuppression intensifies with increasing 
tumor burden. Surgery reduces the quantity of 
immunosuppressive factors, allowing the immune 
response to recover. 
Contrary to the proposed biological mechanisms 
in favour of surgical removal of the primary, there 
have been observation indicating that surgical 
resection of the breast lesion in MBC may 
accelerate relapse by two mechanisms: (1) due to 
removal of inhibitors of angiogenesis, there will be 
an angiogenic surge; (2) surgical wounding will 
lead to the release of growth and 
immunosuppressive factors [8, 9]. 
The aim of this retrospective study was to evaluate 
the impact of surgical therapy of the primary tumor 
on survival outcome in patients with metastatic 
breast cancer and to analyse other prognostic 
factors affecting survival in those patients. 
Patients and Methods 
This retrospective study included all women with 
stage IV breast cancer at time of diagnosis 
presented to Clinical Oncology and Nuclear 
Medicine Department, Mansoura University (MU) 
in the period from January 2000 to December 2008 
inclusive.  
Information recorded for each patient included 
clinical, pathological features, and survival. Staging 
was based on clinical TNM classification [10]. The 
histologic grade was grouped into four categories: 
well differentiated, moderately differentiated, 
poorly differentiated and unknown. Hormone 
receptor status was classified as positive negative 
and unknown. Metastatic site involvement was 
categorized as one or more and in the following 
categories: only bone, only visceral, combination 
of bone and visceral. Additional data included 
Her-2 status positive, negative or unknown as 
assessed by FISH technique. Pathology was 
classified as ductal, lobular and others. Surgical 
interference was categorized as no or yes. 
Overall survival rate was calculated from date of 
diagnosis to date of breast-cancer related death or 
last follow-up. 
Statistical methods: The data were encoded in a 
computer using the Statistical Package for Social 
Sciences (SPSS) version 15.0 (Chicago, IL, USA).  
Distributions of survival functions were estimated 
using the Kaplan-Meier method. Non-normally 
distributed data was expressed as number and 
percentage. Log rank test was used to analyse the 
difference between the curves. P values of <0.05 
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were considered significant. 
Results 
Of 360 patients with stage IV breast cancer at time 
of diagnosis presented to Clinical Oncology and 
Nuclear Medicine Department MU, 30 patients lost 
follow-up. So our study included 330 patients only. 
Forty percent of them (132 patients) were 
undergone surgery of the primary tumor and 60% 
(198 patients) did not. Of the 132 patients who 
were operated, 39 patients (29.5%) were operated 
with curative intent as the distant metastases were 
not apparent before surgery but diagnosed in a 
period of few days to 1 month after surgery. 
All patients underwent mastectomy but axillary 
lymph node dissection was performed in 106 
patients (80%). 
Patients characteristics are listed in Table 1; 
patients ≤50 years were more common (66.7%). 
Positive receptor status and Her-2 amplification 
were recorded in 66% and 50.6% respectively. 
About 74% of patients had one site of metastasis 
and visceral metastases were higher (45%). Median 
overall survival time was statistically significant 
higher (p=0.003) for the surgery (27 months; 
95%CI: 23.247-30.753) versus no surgery group 
(15 months; 95% CI: 12.242-17.758). 
On multivariate analysis, patients with younger age, 
one site of metastasis, bone only metastasis, 
smaller size of the primary tumor, positive receptor 
status, lack of Her-2 amplification and absence of 
lymph node involvement had statistically 
significant higher survival rate. Histologic grade 
and pathological type had insignificant impact on 
survival (p=0.7, 0.82 respectively), Table 2. 
Patients who were operated had higher 
significant survival rate (34 % versus 16 %) Figure 
1. 
 
Table 1 Patients characteristics 
Character No % 
Age: 
  ≤50y 
  >50 y 
 
220 
110 
 
66.7 
33.3 
Hormone receptor status 
  Positive 
  Negative 
  Unknown 
 
218 
66 
46 
 
66.1 
20 
13.9 
Her-2 status 
  Positive 
  Negative 
  Unknown 
 
167 
105 
58 
 
50.6 
31.8 
17.6 
Histologic grade 
  Well differentiated (G1) 
  Moderately differentiated (G2) 
  Poorly differentiated (G3) 
  Unknown 
 
16 
82 
205 
27 
 
4.8 
24.9 
62.1 
8.2 
TNM staging 
  T1/T2 
  T3/T4 
  N0 
  N1/N2/N3 
 
119 
211 
106 
224 
 
36.1 
63.9 
32.1 
67.9 
Pathology 
  Ductal 
  Lobular 
  Others 
 
225 
37 
68 
 
68.2 
11.2 
20.6 
Local surgery 
  No 
  Yes 
 
198 
132 
 
60 
40 
Metastatic site 
  Bony 
  Visceral 
  Both 
 
115 
148 
67 
 
34.8 
44.9 
20.3 
Number of metastatic site 
  1 
  ≥2 
 
247 
83 
 
74.8 
25.2 
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Table 2 multivariate analysis between variables affecting survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Overall survival in both groups 
Character 95% CI P 
Age: 
  ≤50y 
  >50 y 
 
23 (19.84 -26.15) 
16 (13.26-18.73) 
 
0.000 
Hormone receptor status 
  Positive 
  Negative 
 
26(23.41-28.58) 
17 (15.50-18.44) 
 
0.000 
Her-2 status 
  Positive 
  Negative 
 
19(17.25-20.71) 
33(28.03-37.99) 
 
0.000 
Histologic grade 
  Well differentiated (G1) 
  Moderately differentiated (G2) 
  Poorly differentiated (G3) 
 
26 (19.16-34.84) 
23(19.45-26.55) 
21(18.22-23.77) 
 
0.07 
TNM staging 
  T1/T2 
  T3/T4 
  N0 
  N1/N2/N3 
 
29(24.59-33.43) 
18(16.36-19.63) 
 
30(23.79-36.20) 
18(16.46-19.54) 
 
0.000 
 
 
0.000 
Pathology 
  Ductal 
  Lobular 
  Others 
 
22(19.18-24.81) 
20(17.02-22.97) 
19(15.74-22.25) 
 
0.082 
Metastatic site 
  Bony 
  Visceral 
  Both 
 
27(22.09-31.904) 
18(15.83-20.168) 
17(10.7-23.23) 
 
.000 
Number of metastatic site 
  1 
  ≥2 
 
32(28.18-35.81) 
19(17.5-20.49) 
 
.00 
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Discussion 
Several lines of evidence suggest that it is time to 
re-examine the approach to the patient diagnosed 
with distant metastases at the initial breast cancer 
presentation. 
Improved imaging technology has resulted in the 
diagnosis of stage IV disease with considerably 
lower tumor burdens than were seen in the past. 
Also, improvements in systemic therapies for 
women with breast cancer raise the possibility of 
cure for a select groups of patients with stage IV 
and helped to increase 5-year survival from about 
10% in 1970s to about 40% in the late 1990s [11]. 
Data from the National Cancer Database (NCDB) 
and the Surveillance, Epidemiology and End 
Results (SEER) database demonstrate a 5-year 
survival of 26% for patients with stage IV breast 
cancer [12]. 
The present study shows survival gain in 
operated patients, those with younger age, smaller 
tumor size, one site of metastasis, bony metastasis, 
positive receptor status, lack of Her-2 amplification 
and absence of lymph node involvement. Several 
retrospective studies from single institution and 
population databases have demonstrated improved 
survival in women with stage IV disease who 
undergo surgery for an intact primary tumor 
[13-15] that coincided with our results. 
The biological rationale for an improvement in 
survival seen with resection of the primary tumor 
in metastatic breast cancer is based on several lines 
of reasoning. The primary tumor may act as a "seed 
source" for development of new metastases and its 
removal would theoretically diminish the chances 
of disease progression [16]. Decreasing the tumor 
burden by removal of the primary could also 
increase the efficacy of chemotherapy by reducing 
the chances of a resistant clone appearing [8].  
Regarding the timing of surgery (early, after 
response to systemic therapy or later, only if 
indicated for palliation) has been examined, large 
databases such as NCDB and SEER capture the 
first course of treatment most accurately and 
therefore women reported as having had surgical 
therapy would most likely have  received this 
early in their course [17]. 
In addition to improvement in survival with 
mastectomy, an improvement in quality of life 
because of discontinuation of chemotherapy is also 
potential benefit [18]. It is useful to remember that 
the 30 day operative mortality of mastectomy as 
long as the 1970s was 0.35%; major complications 
are infrequent and at present, hospitalizations of 
longer than 2 days after mastectomy are 
uncommon. These morbidity and mortality 
statistics compare favorably with the toxicity 
profiles of many systemic agents used in the 
metastatic setting [19]. However, association 
between surgery and survival could be due to the 
fact that women with favorable disease 
characteristics were often operated [20].  
Multivariate analysis demonstrated a significant 
association between overall survival and younger 
age, smaller tumor size, and positive ER or PR 
status in our study comparable to that found by 
Gnerlich et al. [8]. Only bony metastasis had 
significantly better overall survival. This result is 
consistent with the known indolent course of 
osseous metastasis. 
A large proportion of patients treated with local 
surgery of the primary tumor also underwent a 
lymph node dissection (80%). Few studies showed 
a non significant association with survival in 
patients who underwent lymph node dissection [20] 
while Rapiti et al. [13] suggests a trend toward a 
larger benefit for women had axillary dissection 
which can be explained by decrease tumor burden 
by axillary dissection when there is lymph node 
involvement. 
The main limitation of our study, is its 
retrospective nature i.e. surgery has not been 
assigned by randomization so the only way to 
overcome this problem is to perform a well 
designed prospective study. More specific 
questions of such a trial are the optimal sequencing 
of systemic treatment and surgery and the 
prognostic value of the response of the primary 
tumor to systemic treatment with or without 
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surgery. 
Conclusion 
Removal of the primary tumor in patients with 
primary distant metastatic breast cancer was 
associated with significantly higher survival. 
However, carefully designed prospective 
randomized trials are needed to confirm these 
results. 
References 
1. Cancer incidence in the Netherlands 2011; 
http://www.ikc net. nl/cijfers/index.php? taal= en & 
frequentiemaat=1.30-8-2011. Ref Type: Internet 
Communication. 
2. Donegan WL: Stage IV carcinoma, in Donegan 
WL, Spratt JS (eds): Cancer of the breast. 
Philadelphia, PA, Saunders, El-sevier Science. 
2002, pp 597-600 
3. Amar S, Roy V, Perez EA. Treatment of metastatic 
breast cancer: looking towards the future. Breast 
Cancer Res Treat. 2009, 114:413-422 
4. Budd GT, Cristofanilli M, Ellis MJ, et al. 
Circulating tumor cells versus imaging-predicting 
overall survival in metastatic breast cancer. Cancer 
Res. 2006, 12:6403-6409 
5. Cristofanilli M, Budd GT, Ellis MJ et al. 
Circulating tumor cells, disease progression and 
survival in metastatic breast cancer. N Eng J Med. 
2004, 351:781-91 
6. Cristofanilli M, Hayes DF, Budd GT, et al. 
Circulating tumor cells: a novel prognostic factor 
for newly diagnostic metastatic breast cancer. J 
Clin Oncol. 2005, 23:1420-1430 
7. Danna EA, Sinha P, Gilbert M, et al. Surgical 
removal of primary tumor reverses tumor induced 
immunosuppression despite the presence of 
metastatic disease. Cancer Res. 2004, 64:2205-
2211 
8. Gnerlich J, Jeffe DB, Desphande AD, et al. 
Surgical removal of the primary tumor increases 
overall survival in patients with metastatic breast 
cancer. Analysis of the 1988-2003 SEER data. Ann 
Surg Oncol. 2007, 14:2187-2194 
9. Retsky M, Bonadonna G, Demicheli R, et al. 
Hypothesis: induced angiogenesis after surgery in 
premenopausal node-positive breast cancer patients 
is a major underlying reason why adjuvant 
chemotherapy works particularly well for those 
patients. Breast Cancer Res. 2004, 6:372-374 
10. Oncoline. www. Oncoline.nl, 30-8-2011. Ref Type: 
Internet communication, 2011 
11. Greenberg PA, Hortobagyi GN, Smith TL, et al. 
Long-term follow-up of patients with complete 
remission following combination chemotherapy for 
metastatic breast cancer. J Clin Oncol. 1996, 
14:2197-2205 
12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 
2007. CA cancer J Clin Oncol. 2007, 57:43-66 
13. Rapiti E, Verkooijen HM, Vlastos G, et al. 
Complete excision of primary breast tumor 
improves survival of patients with metastatic breast 
cancer at diagnosis. J Clin Oncol. 2006, 24:2743-
2749 
14. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical 
resection of the primary tumor is associated with 
increased long-term survival in patients with stage 
IV breast cancer after controlling for site of 
metastasis. Ann Surg Oncol. 2007, 14:3345-3351 
15. Ruiterkamp J, Emst MF, vande Poll-Franse LV, et 
al. Surgical resection of the primary tumor is 
associated with improved survival in patients with 
distant metastatic breast cancer at diagnosis. Eur J 
Surg Oncol. 2009, 35:1146-1151 
16. Khan SA, Stewart AK, Morrow M. Does 
aggressive local therapy improve survival in 
metastatic breast cancer? Surgery. 2002, 132:620-
626 
17. Khan SA. Primary tumor resection in stage IV 
breast cancer: consistent benefit or consistent bias? 
Ann Surg Oncol. 2007, 14(12):3285-3287 
18. Pockaj BA, Wasif N, Dueck AC, et al. 
Metastatectomy and surgical resection of the 
primary tumor in patients with stage IV breast 
cancer. Ann Surg Oncol. 2010, 17:2419-26. 
19. Morrow M and Goldstein L. Surgery of the 
primary tumor in metastatic breast cancer: closing 
 Elawadi M et al. American Journal of Cancer Therapy and Pharmacology 2014, 2:1-7 
  
Ivy Union Publishing | http: //www.ivyunion.org February 22, 2014 | Volume 2 | Issue 1  
Page 7 of 7 
the barn door after the horse has bolted? J Clin 
Oncol. 2006, 24:2694-2699 
20. Rashaan ZM, Bastiaannet E, Portielje JEA, et al. 
Surgery in metastatic breast cancer: Patients with a 
favorable profile seem to have the most benefit 
from surgery. EJSO. 2012, 38:52-56 
